Which novel drugs can be used as primary treatment for amyloidosis associated with multiple myeloma (MM)?

Updated: Mar 06, 2020
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

According to National Comprehensive Cancer Network (NCCN) guidelines, novel drugs such as bortezomib can be used with dexamethasone as primary treatment for multiple myeloma–associated amyloidosis. The combination of cyclophosphamide, thalidomide, and dexamethasone is also recommended for the primary treatment of amyloidosis. [2]

The NCCN, American Society of Clinical Oncology (ASCO), and International Myeloma Workshop clinical guidelines for prevention of venous thromboembolism agree that patients with multiple myeloma who are receiving thalidomide- or lenalidomide-based regimens with chemotherapy and/or dexamethasone should receive prophylactic anticoagulation therapy with either aspirin or low molecular weight heparin (LMWH) for lower-risk patients and LMWH for higher-risk patients. [131, 132, 133]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!